Compound preparation for treating hyperuricemia and gout

A hyperuricemia and preparation technology, applied in the field of medicine, can solve problems affecting organ metabolism and fatal adverse reactions

Pending Publication Date: 2021-09-24
浙江歌文达生物医药科技有限公司
View PDF3 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Compound Benzbromarone Tablets, an anti-gout drug already on the market in China, contains two drugs, allopurinol and benzbromarone. Among them, allopurinol is a purine analogue, which affects the metabolism of other organs in the human body, and requires repeated lar

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compound preparation for treating hyperuricemia and gout
  • Compound preparation for treating hyperuricemia and gout
  • Compound preparation for treating hyperuricemia and gout

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0190] The present embodiment 1 provides a kind of compound tablet and preparation method thereof, and described compound tablet prescription is as shown in table 1 below:

[0191] Table 1 Compound Tablet Prescription (1000 Tablets)

[0192]

[0193] The preparation method of the compound tablet of the present embodiment 1

[0194] 1. Adhesive preparation: the povidone of prescription quantity is mixed with water and is prepared into 5% (mass concentration) povidone aqueous solution, as adhesive.

[0195] 2. Weighing and sieving: take the active ingredients of each prescription amount and auxiliary materials except magnesium stearate and povidone respectively, and pass through a 20-mesh sieve to obtain raw and auxiliary materials.

[0196] 3. Pre-mixing: Add the above raw and auxiliary materials into the hopper mixer and pre-mix for 15 minutes.

[0197] 4. Fluidized bed granulation: put the pre-mixed material into the fluidized bed, and use 5% povidone aqueous solution as...

Embodiment 2

[0202] Present embodiment 2 provides a kind of compound tablet and preparation method thereof, and described compound tablet prescription is as shown in table 2 below:

[0203] Table 2 Prescription of Compound Tablets (1000 Tablets)

[0204]

[0205] The compound tablet preparation method of present embodiment 2

[0206] 1. Adhesive preparation: the povidone of prescription quantity is mixed with water and is prepared into 5% (mass concentration) povidone aqueous solution, as adhesive.

[0207] 2. Weighing and sieving: take the active ingredients of each prescription amount and auxiliary materials except magnesium stearate and povidone respectively, and pass through a 20-mesh sieve to obtain raw and auxiliary materials.

[0208] 3. Pre-mixing: Add the above raw and auxiliary materials into the hopper mixer and pre-mix for 15 minutes.

[0209] 4. Fluidized bed granulation: put the pre-mixed material into the fluidized bed, and use 5% povidone aqueous solution as the binder...

Embodiment 3

[0214] Present embodiment 3 provides a kind of compound tablet and preparation method thereof, and described compound tablet prescription is as shown in table 3 below:

[0215] Table 3 Prescription of Compound Tablets (1000 Tablets)

[0216]

[0217] The compound tablet preparation method of present embodiment 3

[0218] 1. Adhesive preparation: the povidone of prescription quantity is mixed with water and is prepared into 5% (mass concentration) povidone aqueous solution, as adhesive.

[0219] 2. Weighing and sieving: take the active ingredients of each prescription amount and auxiliary materials except magnesium stearate and povidone respectively, and pass through a 20-mesh sieve to obtain raw and auxiliary materials.

[0220] 3. Pre-mixing: Add the above raw and auxiliary materials into the hopper mixer and pre-mix for 15 minutes.

[0221] 4. Fluidized bed granulation: put the pre-mixed material into the fluidized bed, and use 5% povidone aqueous solution as the binder...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Hardnessaaaaaaaaaa
Login to view more

Abstract

The invention provides a compound preparation for treating hyperuricemia and gout. Specifically, the invention provides a composition, which comprises (a) a first active ingredient, wherein the first active ingredient is a 1,2,4-triazole compound or a pharmaceutically acceptable salt thereof; and (b) a second active ingredient, wherein the second active ingredient is benzbromarone or a pharmaceutically acceptable salt thereof. The first active ingredient and the second active ingredient can synergistically play a role in treating hyperuricemia and gout and reduce side effects.

Description

technical field [0001] The invention relates to the field of medicines, in particular to a compound preparation for treating hyperuricemia and gout. Background technique [0002] Hyperuricemia (HUA): Hyperuricemia is defined internationally as fasting blood uric acid levels > 420 μmol / L for men and > 360 μmol / L for women under normal purine diet. "2017 China Multidisciplinary Expert Consensus on Diagnosis and Treatment of Hyperuricemia Related Diseases" believes that the saturation concentration of urate in blood is 420 μmoL / L, regardless of gender. deposited in other tissues. Therefore, the consensus defines hyperuricemia as a blood uric acid level >420 μmol / L (7 mg / dl). Gout is a crystal-associated arthropathy caused by the deposition of monosodium urate, which is directly related to hyperuricemia caused by purine metabolic disorders and / or decreased uric acid excretion, mainly including acute onset arthritis and tophi formation , tophaceous chronic arthritis, ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/444A61K31/343A61K9/20A61K9/48A61K9/14A61P19/06
CPCA61K31/444A61K31/343A61K9/2054A61K9/4866A61K9/146A61P19/06A61K2300/00
Inventor 孙庆松王帅周文正李庆豪廖美林宋丹丹邓有文
Owner 浙江歌文达生物医药科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap